Corcept Therapeutics Incorporated (CORT)
Automate Your Wheel Strategy on CORT
With Tiblio's Option Bot, you can configure your own wheel strategy including CORT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CORT
- Rev/Share 7.158
- Book/Share 6.1027
- PB 5.7909
- Debt/Equity 0.0101
- CurrentRatio 3.1413
- ROIC 0.1005
- MktCap 3717351589.0
- FreeCF/Share 1.57
- PFCF 22.8667
- PE 34.789
- Debt/Assets 0.0077
- DivYield 0
- ROE 0.1599
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | CORT | Wolfe Research | Peer Perform | Underperform | -- | $30 | Dec. 31, 2025 |
| Initiation | CORT | UBS | -- | Neutral | -- | -- | Dec. 16, 2025 |
| Initiation | CORT | Wolfe Research | -- | Peer Perform | -- | -- | Nov. 18, 2025 |
News
INVESTOR DEADLINE: Corcept Therapeutics Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
Published: February 24, 2026 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)---- $CORT #CORT--The lawsuit alleges that defendants failed to disclose that the FDA raised concerns about the adequacy of evidence supporting relacorilant's NDA.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated (CORT)
Published: February 24, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northen District of California on behalf of all persons or entities who purchased or otherwise acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) securities between October 31, 2024, and December 30, 2025, inclusive (the “Class Period”).
Read More
INVESTOR DEADLINE: Corcept Therapeutics Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Corcept class action lawsuit seeks to represent purchasers or acquirers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"). Captioned Allegheny County Employees' Retirement System v.
Read More
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is Investigating Possible Securities Claims against Corcept Therapeutics Incorporated
Published: February 10, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Corcept Therapeutics Incorporated (NASDAQ: CORT)? Did you lose money in your investment in Corcept Therapeutics Incorporated?
Read More
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
Published: February 09, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is Investigating Possible Securities Claims against Corcept Therapeutics Incorporated
Published: February 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Corcept Therapeutics Incorporated (NASDAQ: CORT)? Did you lose money in your investment in Corcept Therapeutics Incorporated?
Read More
Lost Money on Corcept Therapeutics Incorporated (CORT)? Possible Fraud - Contact Levi & Korsinsky Today
Published: February 04, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - February 4, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ: CORT) concerning potential violations of the federal securities laws. What Happened?
Read More
Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Published: February 04, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CORCEPT THERAPEUTICS INCORPORATED (CORT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER.
Read More
Allspring Emerging Growth Fund Q4 2025 Performance Review
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Neutral
Allspring Emerging Growth Fund Q4 2025 Performance Review
Read More
Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Published: February 03, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CORCEPT THERAPEUTICS INCORPORATED (CORT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On December 31, 2025, Corcept announc.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Corcept Therapeutics Incorporated – CORT
Published: February 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm
Published: February 02, 2026 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- The latest adverse development for Corcept Therapeutics (NASDAQ: CORT) concerning its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant – came on January 30, 2026 when Reuters reported that the FDA "warned the company 'on several occasions' not to submit its drug application." This news sent the price of Corcept shares tumbling $7.81 (-17%) during trading that day.
Read More
Corcept Therapeutics (CORT) Shares Fall Again Amid Report FDA Warned Several Times Not to Submit Relacorilant Drug Application – Hagens Berman
Published: January 30, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- The latest adverse development for Corcept Therapeutics (NASDAQ: CORT) concerning its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant – came on January 30, 2026 when Reuters reported that the FDA “warned the company ‘on several occasions' not to submit its drug application.” This news sent the price of Corcept shares tumbling $7.81 (-17%) during trading that day.
Read More
Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application
Published: January 30, 2026 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Berman Tabacco, a national law firm representing investors, announces that it is investigating potential securities law violations by Corcept Therapeutics Incorporated (Nasdaq: CORT) (“Corcept” or the “Company”), a company based in Redwood City, California.
Read More
Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Securities Class Action Investigation – CORT
Published: January 30, 2026 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT) resulting from allegations that Corcept may have issued materially misleading business information to the investing public. So What: If you purchased Corcept securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fe.
Read More
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is Investigating Possible Securities Claims against Corcept Therapeutics Incorporated
Published: January 30, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Corcept Theraepeutics Incorporated (NASDAQ: CORT)? Did you lose money in your investment in Corcept Theraepeutics Incorporated?
Read More
Corcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover Losses
Published: January 30, 2026 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Corcept Therapeutics Inc. (Nasdaq: CORT) for potential securities law violations. Investors who have lost money in their Corcept Therapeutics investment should contact the firm to learn more about how they might recover those losses.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Published: January 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Neutral
Corcept jumps after relacorilant plus nab-paclitaxel hits overall survival endpoint in phase III ROSELLA study in platinum-resistant ovarian cancer.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Published: January 22, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Published: January 20, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman
Published: January 14, 2026 by: PRNewsWire
Sentiment: Neutral
Partner Reed Kathrein Urges Investors to Contact Firm SAN FRANCISCO, Jan. 14, 2026 /PRNewswire/ -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter ("CRL") from the FDA for its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant. The news and severe market reaction has prompted national shareholder rights law firm Hagens Berman to commence an investigation into whether Corcept may have misled investors about relacorilant's efficacy and commercial prospects.
Read More
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Corcept Therapeutics Incorporated (CORT)
Published: January 14, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ: CORT) concerning potential violations of the federal securities laws. What Happened?
Read More
CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses
Published: January 13, 2026 by: Newsfile Corp
Sentiment: Neutral
Boston, Massachusetts--(Newsfile Corp. - January 13, 2026) - Block & Leviton is investigating Corcept Therapeutics Inc. (NASDAQ: CORT) for potential securities law violations. Investors who have lost money in their Corcept Therapeutics investment should contact the firm to learn more about how they might recover those losses.
Read More
Scott+Scott Attorneys at Law LLP Announces Its Investigation Into Corcept Therapeutics Incorporated (CORT)
Published: January 12, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - January 12, 2026) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders.
Read More
CORT Investor ALERT: Corcept Therapeutics Inc. Investigated for Securities Fraud; Investors Should Contact Block & Leviton To Potentially Recover Losses
Published: January 12, 2026 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Corcept Therapeutics Inc. (Nasdaq: CORT) for potential securities law violations. Investors who have lost money in their Corcept Therapeutics investment should contact the firm to learn more about how they might recover those losses.
Read More
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman
Published: January 09, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter (“CRL”) from the FDA for its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Published: January 08, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Corcept Therapeutics Incorporated (CORT)
Published: January 07, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - January 7, 2026) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders.
Read More
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman
Published: January 06, 2026 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO, Jan. 6, 2026 /PRNewswire/ -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter ("CRL") from the FDA for its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant. The news and severe market reaction has prompted national shareholder rights law firm Hagens Berman to commence an investigation into whether Corcept may have misled investors about relacorilant's efficacy and commercial prospects.
Read More
About Corcept Therapeutics Incorporated (CORT)
- IPO Date 2004-04-14
- Website https://www.corcept.com
- Industry Biotechnology
- CEO Joseph K. Belanoff
- Employees 500